Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Turing's Shkreli Caves To Pressure; Lowering Daraprim Price

This article was originally published in Scrip

Executive Summary

Martin Shkreli, the hedge funder-turned-pharma CEO, who jacked up the price of a rare disease medicine from $13.50 to $750 per pill after acquiring it last month, found out the hard way that picking a fight with the HIV/AIDS advocacy community and presidential candidates already on the war path about skyrocketing drug prices wasn't the best idea.



Related Companies